Interaction between bone morphogenetic proteins and endothelin-1 in human pulmonary artery smooth muscle

Vascular Pharmacology

Volumn 51, Issue 5-6, 2009, Pages 344-349

  Din, Sarah ^a   Sarathchandra, Padmini ^a   Yacoub, Magdi H ^a   Chester, Adrian H ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Endothelium; Hypertension; Lung; Smooth muscle; Vasoconstriction

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 4; BONE MORPHOGENETIC PROTEIN RECEPTOR 7; ENDOTHELIN 1; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY MUSCLE; ARTERY WALL; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ARTERY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PULMONARY HYPERTENSION; SMOOTH MUSCLE CONTRACTION;

ADULT; AGED; BONE MORPHOGENETIC PROTEIN 7; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PULMONARY ARTERY; VASOCONSTRICTION;

EID: 70449093717     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.09.001     Document Type: Article

References (32)

1. Archer S., and Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 102 (2000) 2781-2791
2. Atkinson C., Stewart S., Upton P.D., Machado R., Thomson J.R., Trembath R.C., and Morrell N.W. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105 (2002) 1672-1678
3. Brand N.J., Roy A., Hoare G., Chester A., and Yacoub M.H. Cultured interstitial cells from human heart valves express both specific skeletal muscle and non-muscle markers. Int. J. Biochem. Cell Biol. 38 (2006) 30-42
4. Bundy R., Marczin N., Chester A.H., and Yacoub M. Differential regulation of DNA synthesis by nitric oxide and hydroxyurea in vascular smooth muscle cells. Am. J. Physiol. 277 (1999) H1799-H1807
5. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., Badesch D.B., Roux S., Rainisio M., Bodin F., and Rubin L.J. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
6. Chazova I., Loyd J.E., Zhdanov V.S., Newman J.H., Belenkov Y., and Meyrick B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am. J. Pathol. 146 (1995) 389-397
7. Chester A.H., O'Neil G.S., Allen S.P., Luu T.N., Tadjkarimi S., and Yacoub M.H. Effect of endothelin on normal and diseased human coronary arteries. Eur. J. Clin. Invest. 22 (1992) 210-213
8. Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G., Kalachikov S., Cayanis E., Fischer S.G., Barst R.J., Hodge S.E., and Knowles J.A. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67 (2000) 737-744
9. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W.P., and Stewart D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328 (1993) 1732-1739
10. Lane K.B., Machado R.D., Pauciulo M.W., Thomson J.R., Phillips III J.A., Loyd J.E., Nichols W.C., and Trembath R.C. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet. 26 (2000) 81-84
11. Langleben D., Dupuis J., Langleben I., Hirsch A.M., Baron M., Senecal J.L., and Giovinazzo M. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 129 (2006) 689-695
12. Latif N., Sarathchandra P., Thomas P.S., Antoniw J., Batten P., Chester A.H., Taylor P.M., and Yacoub M.H. Characterization of structural and signaling molecules by human valve interstitial cells and comparison to human mesenchymal stem cells. J. Heart Valve Dis. 16 (2007) 56-66
13. Machado R.D., Pauciulo M.W., Thomson J.R., Lane K.B., Morgan N.V., Wheeler L., Phillips III J.A., Newman J., Williams D., Galie N., Manes A., McNeil K., Yacoub M., Mikhail G., Rogers P., Corris P., Humbert M., Donnai D., Martensson G., Tranebjaerg L., Loyd J.E., Trembath R.C., and Nichols W.C. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 68 (2001) 92-102
14. Mikhail G., Chester A.H., Gibbs J.S., Borland J.A., Banner N.R., and Yacoub M.H. Role of vasoactive mediators in primary and secondary pulmonary hypertension. Am. J. Cardiol. 82 (1998) 254-255
15. Miriyala S., Gongora Nieto M.C., Mingone C., Smith D., Dikalov S., Harrison D.G., and Jo H. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 113 (2006) 2818-2825
16. Morrell N.W., and Wilkins M.R. Genetic and molecular mechanisms of pulmonary hypertension. Clin. Med. 1 (2001) 138-145
17. Morrell N.W., Yang X., Upton P.D., Jourdan K.B., Morgan N., Sheares K.K., and Trembath R.C. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 104 (2001) 790-795
18. Nakaoka T., Gonda K., Ogita T., Otawara-Hamamoto Y., Okabe F., Kira Y., Harii K., Miyazono K., Takuwa Y., and Fujita T. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J. Clin. Invest. 100 (1997) 2824-2832
19. Reynolds A.M., Xia W., Holmes M.D., Hodge S.J., Danilov S., Curiel D.T., Morrell N.W., and Reynolds P.N. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am. J. Physiol., Lung Cell. Mol. Physiol. 292 (2007) L1182-L1192
20. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., and Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346 (2002) 896-903
21. Sorescu G.P., Sykes M., Weiss D., Platt M.O., Saha A., Hwang J., Boyd N., Boo Y.C., Vega J.D., Taylor W.R., and Jo H. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J. Biol. Chem. 278 (2003) 31128-31135
22. Sorescu G.P., Song H., Tressel S.L., Hwang J., Dikalov S., Smith D.A., Boyd N.L., Platt M.O., Lassegue B., Griendling K.K., and Jo H. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ. Res. 95 (2004) 773-779
23. Star G.P., Giovinazzo M., and Langleben D. Effects of bone morphogenic proteins and transforming growth factor-beta on in-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vascul. Pharmacol. 50 (2009) 40-45
24. Stewart D.J., Levy R.D., Cernacek P., and Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann. Intern. Med. 114 (1991) 464-469
25. Teichert-Kuliszewska K., Kutryk M.J., Kuliszewski M.A., Karoubi G., Courtman D.W., Zucco L., Granton J., and Stewart D.J. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ. Res. 98 (2006) 209-217
26. Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M., Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J., Wheeler L., Higenbottam T., Gibbs J.S., Egan J., Crozier A., Peacock A., Allcock R., Corris P., Loyd J.E., Trembath R.C., and Nichols W.C. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J. Med. Genet. 37 (2000) 741-745
27. Upton P.D., Long L., Trembath R.C., and Morrell N.W. Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells. Mol. Pharmacol. 73 (2008) 539-552
28. Willette R.N., Gu J.L., Lysko P.G., Anderson K.M., Minehart H., and Yue T. BMP-2 gene expression and effects on human vascular smooth muscle cells. J. Vasc. Res. 36 (1999) 120-125
29. Wong G.A., Tang V., El Sabeawy F., and Weiss R.H. BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1. Am. J. Physiol. Endocrinol. Metab. 284 (2003) E972-E979
30. Yu P.B., Beppu H., Kawai N., Li E., and Bloch K.D. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J. Biol. Chem. 280 (2005) 24443-24450
31. Zeisberg M., Hanai J., Sugimoto H., Mammoto T., Charytan D., Strutz F., and Kalluri R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9 (2003) 964-968
32. Zhang Z.D., and Cox G. MTT assay overestimates human airway smooth muscle cell number in culture. Biochem. Mol. Biol. Int. 38 (1996) 431-436